154 related articles for article (PubMed ID: 19663790)
1. Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity.
Shi Q; Shih CC; Lee KH
Anticancer Agents Med Chem; 2009 Oct; 9(8):904-12. PubMed ID: 19663790
[TBL] [Abstract][Full Text] [Related]
2. ASC-J9
Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C
Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687
[TBL] [Abstract][Full Text] [Related]
3. A review of the effects and molecular mechanisms of dimethylcurcumin (ASC-J9) on androgen receptor-related diseases.
Hu H; Zhou H; Xu D
Chem Biol Drug Des; 2021 Apr; 97(4):821-835. PubMed ID: 33277796
[TBL] [Abstract][Full Text] [Related]
4. Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation.
Zhou DY; Ding N; Du ZY; Cui XX; Wang H; Wei XC; Conney AH; Zhang K; Zheng X
Mol Med Rep; 2014 Sep; 10(3):1315-22. PubMed ID: 25060817
[TBL] [Abstract][Full Text] [Related]
5. Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer.
Wen S; Chang HC; Tian J; Shang Z; Niu Y; Chang C
Am J Pathol; 2015 Feb; 185(2):293-301. PubMed ID: 25432062
[TBL] [Abstract][Full Text] [Related]
6. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.
Luo J; Tian J; Chou F; Lin C; Xing EZ; Zuo L; Niu Y; Yeh S; Chang C
Cancer Lett; 2019 Mar; 444():35-44. PubMed ID: 30248372
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor (AR) degradation enhancer ASC-J9
Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C
Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251
[TBL] [Abstract][Full Text] [Related]
8. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.
McCarty MF; Hejazi J; Rastmanesh R
Integr Cancer Ther; 2014 Sep; 13(5):386-95. PubMed ID: 24867960
[TBL] [Abstract][Full Text] [Related]
9. Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulating the expression of IkappaBalpha, c-Jun and androgen receptor.
Guo H; Xu YM; Ye ZQ; Yu JH; Hu XY
Pharmazie; 2013 Jun; 68(6):431-4. PubMed ID: 23875250
[TBL] [Abstract][Full Text] [Related]
10. Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells.
Choi HY; Lim JE; Hong JH
Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):343-9. PubMed ID: 20680030
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor - Synergistic action of quercetin and curcumin.
Sharma V; Kumar L; Mohanty SK; Maikhuri JP; Rajender S; Gupta G
Mol Cell Endocrinol; 2016 Aug; 431():12-23. PubMed ID: 27132804
[TBL] [Abstract][Full Text] [Related]
12. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C
EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
[TBL] [Abstract][Full Text] [Related]
13. Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents.
Lin L; Shi Q; Nyarko AK; Bastow KF; Wu CC; Su CY; Shih CC; Lee KH
J Med Chem; 2006 Jun; 49(13):3963-72. PubMed ID: 16789753
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein.
Dorai T; Gehani N; Katz A
Mol Urol; 2000; 4(1):1-6. PubMed ID: 10851300
[TBL] [Abstract][Full Text] [Related]
15. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents.
Ohtsu H; Xiao Z; Ishida J; Nagai M; Wang HK; Itokawa H; Su CY; Shih C; Chiang T; Chang E; Lee Y; Tsai MY; Chang C; Lee KH
J Med Chem; 2002 Nov; 45(23):5037-42. PubMed ID: 12408714
[TBL] [Abstract][Full Text] [Related]
16. [ASC-J9 for castration-resistant prostate cancer].
Yamashita S; Arai Y
Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
[TBL] [Abstract][Full Text] [Related]
17. Biological and pharmacological evaluation of dimethoxycurcumin: A metabolically stable curcumin analogue with a promising therapeutic potential.
Teymouri M; Barati N; Pirro M; Sahebkar A
J Cell Physiol; 2018 Jan; 233(1):124-140. PubMed ID: 27996095
[TBL] [Abstract][Full Text] [Related]
18. Delivery of curcumin within emulsome nanoparticles enhances the anti-cancer activity in androgen-dependent prostate cancer cell.
Bolat ZB; Islek Z; Sahin F; Ucisik MH
Mol Biol Rep; 2023 Mar; 50(3):2531-2543. PubMed ID: 36607480
[TBL] [Abstract][Full Text] [Related]
19. Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts.
Hong JH; Lee G; Choi HY
Korean J Urol; 2015 Sep; 56(9):656-65. PubMed ID: 26366279
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.
Tam KJ; Dalal K; Hsing M; Cheng CW; Khosravi S; Yenki P; Tse C; Peacock JW; Sharma A; Chiang YT; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Oncotarget; 2017 Feb; 8(6):9617-9633. PubMed ID: 28038451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
